No Data
No Data
Ventyx Biosciences GAAP EPS of -$0.41 Beats by $0.12
Ventyx Biosciences | 10-K: Annual report
Ventyx Biosciences | 8-K: Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress
Express News | Ventyx Biosciences Q4 Net Income USD -29.351 Million
Express News | Ventyx Biosciences Announces Presentation of Data From the Phase 2 Trial of Allosteric Tyk2 Inhibitor Vtx958 in Crohn’s Disease at Ecco 2025
Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference